Core Viewpoint - A class action lawsuit has been filed against V.F. Corporation (VFC) for allegedly misleading investors regarding its turnaround plan, particularly concerning the Vans brand [1][3]. Company Overview - VFC is a global leader in branded lifestyle apparel, footwear, and accessories, owning well-known brands such as Vans, The North Face, Timberland, and JanSport [2]. Lawsuit Details - The lawsuit pertains to investors who purchased VFC shares between October 30, 2023, and May 20, 2025, with a deadline of November 12, 2025, for potential lead plaintiff appointments [2]. - The complaint claims that VFC did not disclose necessary restructuring steps for Vans, which negatively impacted revenue and contradicted earlier public statements [3]. Financial Performance - On May 21, 2025, VFC reported a 20% decline in Vans revenue for Q4 fiscal 2025, worsening from an 8% decline in the previous quarter [4]. - The company attributed this shortfall to undisclosed internal cost-cutting and restructuring actions, indicating deeper brand issues [4]. - Following the revenue announcement, VFC's stock price dropped from $14.43 to $12.15, a decline of over 15% [4].

Group 1 - The core issue involves a securities fraud investigation against Spectrum Pharmaceuticals, Inc. related to misleading statements about its Pinnacle Study for the drug poziotinib, aimed at lung cancer treatment [3] - The class action lawsuit pertains to investors who acquired Spectrum shares between March 17, 2022, and September 22, 2022, during which the company faced significant challenges [1][2] - Spectrum's shares were delisted following its merger with Assertio Holdings, Inc., indicating potential financial instability and regulatory scrutiny [3] Group 2 - Investors have a deadline of September 24, 2025, to seek appointment as lead plaintiff representatives in the class action [2] - Berger Montague PC, a law firm with extensive experience in securities class action litigation, is leading the investigation on behalf of affected investors [5]

Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly overstating its competitive position and providing unrealistic financial guidance for 2025, leading to significant investor losses when the truth was revealed [3]. Company Overview - LifeMD, Inc. is headquartered in New York and specializes in providing virtual medical services and prescription delivery [2]. Lawsuit Details - The lawsuit covers investors who purchased LifeMD shares from May 7, 2025, to August 5, 2025, and claims that the company failed to disclose rising customer acquisition costs associated with its RexMD platform and its promotion of obesity medications like Wegovy and Zepbound [3]. - The complaint asserts that LifeMD's statements during the class period were materially false and misleading, lacking a reasonable basis [3]. Investor Information - Investors who acquired LifeMD securities during the class period have until October 27, 2025, to seek appointment as lead plaintiff representatives [2].

Core Viewpoint - A class action lawsuit has been filed against C3.ai, Inc. on behalf of investors who purchased shares during the specified class period, following the company's disappointing financial disclosures and leadership issues [1][3]. Group 1: Class Action Lawsuit - The lawsuit is initiated by Berger Montague PC for investors who acquired C3.ai shares from February 26, 2025, to August 8, 2025 [1][2]. - Investors have until October 21, 2025, to seek appointment as lead plaintiff representative of the class [2]. Group 2: Financial Performance - On August 8, 2025, C3.ai reported weak preliminary financial results for Q1 FY2026 and lowered its full-year revenue guidance, citing leadership changes and the CEO's health as contributing factors [3]. - Following the announcement, C3.ai's stock price fell from $22.13 to $16.47, marking a one-day loss of over 25% [3]. Group 3: Company Overview - C3.ai is based in Redwood City, California, and specializes in delivering scalable enterprise AI applications for various sectors, including commercial, industrial, and government [2].

Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly making materially false and misleading statements regarding its business and financial outlook during the specified class period [1][3]. Company Overview - LifeMD, Inc. is a telehealth provider based in New York, offering direct-to-patient virtual care and pharmacy services [2]. Allegations - The lawsuit claims that LifeMD overstated its competitive position and raised its 2025 guidance without properly accounting for increasing customer acquisition costs, particularly in its RexMD segment and for obesity-related drugs like Wegovy and Zepbound [3]. - Following the revelation of the true facts, LifeMD's shares experienced a significant decline of 44%, equating to a drop of $5.31 per share in a single trading session [3]. Investor Information - Investors who acquired LifeMD securities during the class period have until October 27, 2025, to seek appointment as lead plaintiff representative of the class [2].

Core Viewpoint - A class action lawsuit has been filed against C3.ai, Inc. by Berger Montague PC on behalf of investors who acquired shares during the specified class period, alleging misleading statements regarding the company's growth and CEO's health [1][3]. Company Overview - C3.ai, headquartered in Redwood City, California, is recognized as a leading provider of enterprise artificial intelligence software [2]. Legal Action Details - The lawsuit claims that C3.ai and certain executives made materially false and misleading statements or failed to disclose adverse information about the company's growth prospects and the impact of the CEO's health on operations [3]. - Investors who purchased C3.ai securities during the class period have until October 21, 2025, to seek appointment as lead plaintiff representatives [2]. Financial Impact - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its full-year revenue guidance, attributing this to leadership reorganization and the CEO's health [3]. - Following this announcement, C3.ai's stock price fell from $22.13 per share on August 8 to $16.47 per share on August 11, marking a decline of over 25% [3].

Group 1 - A class action lawsuit has been filed against C3.ai, Inc. on behalf of investors who purchased shares between February 26, 2025, and August 8, 2025 [1][2] - C3.ai is an artificial intelligence technology company based in Redwood City, California, providing scalable enterprise AI applications for various sectors [2] - On August 8, 2025, C3.ai reported weak preliminary financial results for Q1 FY2026 and lowered its full-year revenue guidance, citing leadership changes and the CEO's health as contributing factors [3] Group 2 - Following the announcement of the weak financial results, C3.ai's stock price fell from $22.13 to $16.47, representing a one-day loss of over 25% [3]

Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly overstating its competitive position and failing to account for rising customer acquisition costs, leading to a significant drop in share value [1][3]. Company Overview - LifeMD, Inc. is a direct-to-consumer telehealth company based in New York, providing virtual healthcare services and pharmacy offerings in areas such as men's health, obesity treatment, and chronic care [2]. Legal Action Details - The lawsuit is on behalf of investors who purchased LifeMD shares between May 7, 2025, and August 5, 2025, with a deadline of October 27, 2025, for investors to seek lead plaintiff status [1][2]. - The complaint claims that LifeMD raised its 2025 guidance recklessly, which contributed to the misrepresentation of its financial health [3]. Financial Impact - Following the revelation of the company's financial issues, LifeMD shares experienced a dramatic decline, losing 44% of their value in a single trading session [3].

Core Viewpoint - A class action lawsuit has been filed against C3.ai, Inc. by Berger Montague on behalf of investors who acquired shares during the specified class period, alleging misleading statements regarding the company's growth and CEO's health [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased C3.ai shares from February 26, 2025, to August 8, 2025 [1][2]. - Investors have until October 21, 2025, to seek appointment as lead plaintiff [2]. Group 2: Allegations Against C3.ai - The complaint claims that C3.ai and its executives made materially false statements and failed to disclose adverse information about the company's growth prospects and the CEO's health [3]. - On August 8, 2025, C3.ai announced disappointing preliminary financial results for Q1 of fiscal 2026 and reduced its full-year revenue guidance, attributing this to leadership reorganization and the CEO's health [3]. Group 3: Stock Price Impact - Following the announcement on August 8, 2025, C3.ai's stock price fell from $22.13 per share to $16.47 per share by August 11, representing a decline of over 25% [3].

Core Viewpoint - National plaintiffs' law firm Berger Montague PC is investigating securities fraud claims against Spectrum Pharmaceuticals, Inc. on behalf of investors who acquired shares during the specified class period [1][2] Group 1: Legal Action - A class action lawsuit has been filed alleging that Spectrum made false or misleading statements regarding its Pinnacle Study, which involved the drug poziotinib for lung cancer treatment [3] - Investors who purchased Spectrum securities during the class period have until September 24, 2025, to seek appointment as lead plaintiff representative [2] Group 2: Company Background - Spectrum Pharmaceuticals is a biopharmaceutical company focused on oncology treatments [2] - The company's shares were delisted following its merger with Assertio Holdings, Inc. [3]